Neumora Therapeutics, Inc.
Neumora Therapeutics (Nasdaq: NMRA) is a clinical-stage biopharmaceutical company developing therapies for brain and centrally mediated diseases and metabolic disorders. Its pipeline includes navacaprant, an oral kappa opioid receptor antagonist in Phase 3 development for major depressive disorder; NMRA-511, a… From the company’s description.
In fiscal 2025, Neumora Therapeutics, Inc. reported a net loss of $236.93M. Operations used $206.44M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Neumora Therapeutics, Inc. does
In the company’s own words
Neumora Therapeutics (Nasdaq: NMRA) is a clinical-stage biopharmaceutical company developing therapies for brain and centrally mediated diseases and metabolic disorders. Its pipeline includes navacaprant, an oral kappa opioid receptor antagonist in Phase 3 development for major depressive disorder; NMRA-511, a vasopressin 1a receptor antagonist for agitation associated with Alzheimer’s disease; NMRA-898, an M4 positive allosteric modulator for schizophrenia; and NMRA-215, a brain-penetrant NLRP3 inhibitor for obesity. Earlier-stage programs target Parkinson’s disease and amyotrophic lateral sclerosis. Neumora combines internal drug discovery with licensed programs and applies data-driven methods to identify and monitor patient populations. Its principal programs span neuropsychiatric, neurodegenerative and metabolic conditions; it does not report operating segments or segment revenue shares. The company acquired BlackThorn in 2020, gaining rights to programs including navacaprant and NMRA-511. As of December 31, 2025, its intellectual property portfolio included more than 400 owned, co-owned or exclusively licensed patents and pending applications. Its website is https://www.neumoratx.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- WATERTOWN, MA
- Fiscal year end
- December
- CIK
- 1885522
- SIC
- 2836
Financial performance, year by year
Fiscal 2023–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Neumora Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Neumora Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Neumora Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Neumora Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Neumora Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”